Literature DB >> 15781977

Techniques for brain imaging in vivo.

Monica Garcia-Alloza1, Brian J Bacskai.   

Abstract

Brain imaging technologies provide an unparalleled tool to assess the physiological and pathological changes in the central nervous system. The aim of this work is to review the technical characteristics of widely used imaging technologies, such as magnetic resonance imaging (MRI), positron emission tomography (PET), or single photon emission computed tomography (SPECT), as well as their utility in clinical diagnosis and follow-up of different neurological disorders. High-resolution developments of MRI and PET, as well as the more recent imaging technology, multiphoton microscopy, for small animal imaging are also analyzed, as rodent models offer an enormous opportunity to study not only the underlying mechanisms of Alzheimer's disease, Parkinson's disease, depression, and schizophrenia among others, but also potential new treatments for all these diseases.

Entities:  

Mesh:

Year:  2004        PMID: 15781977     DOI: 10.1385/NMM:6:1:065

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  100 in total

1.  Quantitative MRI of the hippocampus and amygdala in severe depression.

Authors:  E Mervaala; J Föhr; M Könönen; M Valkonen-Korhonen; P Vainio; K Partanen; J Partanen; J Tiihonen; H Viinamäki; A K Karjalainen; J Lehtonen
Journal:  Psychol Med       Date:  2000-01       Impact factor: 7.723

2.  Two-photon laser scanning fluorescence microscopy.

Authors:  W Denk; J H Strickler; W W Webb
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

3.  The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease.

Authors:  S P Hume; A A Lammertsma; R Myers; S Rajeswaran; P M Bloomfield; S Ashworth; R A Fricker; E M Torres; I Watson; T Jones
Journal:  J Neurosci Methods       Date:  1996-08       Impact factor: 2.390

4.  Huntington's disease progression. PET and clinical observations.

Authors:  T C Andrews; R A Weeks; N Turjanski; R N Gunn; L H Watkins; B Sahakian; J R Hodges; A E Rosser; N W Wood; D J Brooks
Journal:  Brain       Date:  1999-12       Impact factor: 13.501

5.  123Iodo-MK-801: a spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease.

Authors:  D R Brown; D J Wyper; J Owens; J Patterson; R C Kelly; R Hunter; J McCulloch
Journal:  J Psychiatr Res       Date:  1997 Nov-Dec       Impact factor: 4.791

6.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

Authors:  Y Okubo; T Suhara; K Suzuki; K Kobayashi; O Inoue; O Terasaki; Y Someya; T Sassa; Y Sudo; E Matsushima; M Iyo; Y Tateno; M Toru
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

7.  Magnetic resonance imaging of neuronal grafts in the primate.

Authors:  N E Simmons; G A Helm; W S Cail; J P Bennett; J A Jane
Journal:  Exp Neurol       Date:  1994-01       Impact factor: 5.330

8.  Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques.

Authors:  Joseph F Poduslo; Geoffry L Curran; Jane A Peterson; Daniel J McCormick; Abdul H Fauq; Murad A Khan; Thomas M Wengenack
Journal:  Biochemistry       Date:  2004-05-25       Impact factor: 3.162

9.  A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.

Authors:  David Mamo; Shitij Kapur; C M Shammi; George Papatheodorou; Steve Mann; François Therrien; Gary Remington
Journal:  Am J Psychiatry       Date:  2004-05       Impact factor: 18.112

10.  5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study.

Authors:  Cristina Messa; Cristina Colombo; Rosa Maria Moresco; Clara Gobbo; Laura Galli; Giovanni Lucignani; Maria Carla Gilardi; Giovanna Rizzo; Enrico Smeraldi; Raffaella Zanardi; Francesc Artigas; Ferruccio Fazio
Journal:  Psychopharmacology (Berl)       Date:  2003-03-11       Impact factor: 4.530

View more
  6 in total

Review 1.  Fluorescent resonance energy transfer: A tool for probing molecular cell-biomaterial interactions in three dimensions.

Authors:  Nathaniel D Huebsch; David J Mooney
Journal:  Biomaterials       Date:  2007-01-16       Impact factor: 12.479

2.  Rational design of amyloid binding agents based on the molecular rotor motif.

Authors:  Jeyanthy Sutharsan; Marianna Dakanali; Christina C Capule; Mark A Haidekker; Jerry Yang; Emmanuel A Theodorakis
Journal:  ChemMedChem       Date:  2010-01       Impact factor: 3.466

Review 3.  Multiphoton in vivo imaging of amyloid in animal models of Alzheimer's disease.

Authors:  Jinghui Dong; Raquel Revilla-Sanchez; Stephen Moss; Philip G Haydon
Journal:  Neuropharmacology       Date:  2010-04-14       Impact factor: 5.250

Review 4.  APP transgenic mice: their use and limitations.

Authors:  Claudia Balducci; Gianluigi Forloni
Journal:  Neuromolecular Med       Date:  2010-12-09       Impact factor: 3.843

5.  Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.

Authors:  Gary W Small; Prabha Siddarth; Daniel H S Silverman; Linda M Ercoli; Karen J Miller; Helen Lavretsky; Susan Y Bookheimer; S-C Huang; Jorge R Barrio; Michael E Phelps
Journal:  Am J Geriatr Psychiatry       Date:  2008-12       Impact factor: 4.105

6.  In Vivo Imaging of Microglia With Multiphoton Microscopy.

Authors:  Carmen Hierro-Bujalance; Brian J Bacskai; Monica Garcia-Alloza
Journal:  Front Aging Neurosci       Date:  2018-07-19       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.